Meet Immatics BD and R&D at CAR-TCR Summit 2017!
Immatics US Inc., CSO, Steffen Walter will be presenting Immatics’ adoptive cell therapy programs directed against XPRESIDENT® derived tumor targets in the “Adoptive T Cell Therapy” track:
Wednesday, Sept 6
11.50am – 12.20pm
“Novel Targets and T-Cell Receptors for Adoptive Cell Therapy”
Steffen Walter (CSO), Immatics